Form 4: Sionna Therapeutics Director Granted Stock Options Valued at $16.99 Per Share

Sionna Therapeutics, Inc. director Marcella K. Ruddy was granted non-qualified stock options to purchase 19,959 shares of common stock at an exercise price of $16.99 per share, with vesting tied to continued service.

Summary

• Marcella K. Ruddy, a Director of Sionna Therapeutics, Inc. (SION), was granted non-qualified stock options.
• The transaction occurred on June 12, 2025.
• The options allow the purchase of 19,959 shares of Sionna Therapeutics common stock.
• The exercise price for these options is $16.99 per share.
• The options vest in full upon the earlier of June 12, 2026, or the date of the next annual meeting of Sionna Therapeutics, Inc., contingent on Ms. Ruddy's continued service.
• The options have an expiration date of June 11, 2035.
• Following this transaction, Ms. Ruddy beneficially owns 19,959 derivative securities directly.

Sentiment

Score: 6

Explanation: The sentiment is slightly positive as the grant of stock options to a director is a routine compensation event that aligns the director's interests with the company's long-term performance and shareholder value, contributing to board stability and motivation.

Positives

• The grant of stock options to a director aligns their interests with those of the shareholders, incentivizing long-term performance and retention.
• The options provide a form of compensation to the director, which is standard practice for public companies.

Negatives

• There are no direct negative implications for the company or its stock price explicitly stated in this Form 4 filing.

Future Outlook

The document indicates that the granted stock options will vest upon the earlier of June 12, 2026, or the date of the next annual meeting of Sionna Therapeutics, Inc., contingent on the reporting person's continued service.

Industry Context

This filing is a routine disclosure of an equity compensation grant to a director, common practice across various industries to attract and retain qualified board members and align their incentives with company performance.

Related Party Transactions

• The document details a transaction where Sionna Therapeutics, Inc. granted stock options to Marcella K. Ruddy, a director of the company. This constitutes a transaction between the company and a related party (a director).

Stakeholder Impact

• Shareholders: The grant aligns the director's financial interests with the company's stock performance, potentially leading to more focused decision-making aimed at increasing shareholder value. However, future exercise of options could lead to minor dilution.
• Employees: This specific filing does not directly impact general employees, as it pertains to director compensation.

Next Steps

• The granted stock options are subject to a vesting schedule, with full vesting occurring upon the earlier of June 12, 2026, or the date of the next annual meeting of Sionna Therapeutics, Inc., provided the director continues service.
• Upon vesting, the director will have the right to exercise the options to purchase common stock at the specified exercise price before the expiration date of June 11, 2035.

Key Dates

Keywords

Sionna Therapeutics, SION, SEC Form 4, Stock Option Grant, Director Compensation, Equity Grant, Marcella K. Ruddy, Insider Transaction